From: Antibody engineering to develop new antirheumatic therapies
mAb category | Suffix | Examples | Specificity | Reference |
---|---|---|---|---|
Chimeric | -ximab | Infliximab (Remicade®) | TNF-α | [59] |
 |  | Rituximab (Rituxan®, Mabthera®) | CD20 | [60] |
Humanised | -zumab | Alemtuzumab (MabCampath®) | CD52 | [18] |
 |  | Tocilizumab (RoActemra®) | IL-6R | [61] |
 |  | Ocrelizumab | CD20 | [62] |
 |  | Epratuzumab | CD22 | [63] |
 |  | Certolizumab pegol (PEGylated Fab fragment) (Cimzia®) | TNF-α | [64] |
 |  | Otelixizumab (Aglycosyl) | CD3 | [42] |
 |  | Teplizumab (Fc-mutated) | CD3 | [65] |
 |  | Visilizumab (Fc-mutated) | CD3 | [44] |
'Fully human' | -mumab | Adalimumab (Humira®) | TNF-α | [66] |
 |  | Ofatumumab (Humax-CD20®) | CD20 | [67] |
 |  | Belimumab (LymphoStat-B®) | BLyS | [68] |
 |  | Golimumab | TNF-α | [69] |
Fusion proteins | -cept | Etanercept (Enbrel®) | TNF-α | [70] |
 |  | Abatacept (Orencia®) | CD80/CD86 | [71] |
 |  | Atacicept | BLyS/BAFF | [72] |